Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Nov;26(11):1399-1407.
doi: 10.1111/ene.14008. Epub 2019 Jul 4.

COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015): an ongoing global Parkinson's disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation

D Santos García  1 , S Jesús  2 , M Aguilar  3 , L L Planellas  4 , J García Caldentey  5 , N Caballol  6 , I Legarda  7 , J Hernández Vara  8 , I Cabo  9 , L López Manzanares  10 , I González Aramburu  11 , M A Ávila Rivera  12 , M J Catalán  13 , L López Díaz  14 , V Puente  15 , J M García Moreno  16 , C Borrué  17 , B Solano Vila  18 , M Álvarez Sauco  19 , L Vela  20 , S Escalante  21 , E Cubo  22 , F Carrillo Padilla  23 , J C Martínez Castrillo  24 , P Sánchez Alonso  25 , M G Alonso Losada  26 , N López Ariztegui  27 , I Gastón  28 , J Kulisevsky  29 , M Menéndez González  30 , M Seijo  9 , J Rúiz Martínez  31 , C Valero  32 , M Kurtis  33 , O de Fábregues-Boixar  8 , J González Ardura  34 , C Prieto Jurczynska  35 , P Martinez-Martin  36 , P Mir  2 ; COPPADIS Study Group
Collaborators, Affiliations
Observational Study

COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015): an ongoing global Parkinson's disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation

D Santos García et al. Eur J Neurol. 2019 Nov.

Abstract

Background and purpose: In Parkinson's disease (PD), the course of the disorder is highly variable between patients. Well-designed, prospective studies for identifying PD progression biomarkers are necessary. Our aim was to show the results of baseline evaluations of an ongoing global PD project, COPPADIS-2015 (Cohort of Patients with PArkinson's DIsease in Spain, 2015).

Methods: This was an observational, descriptive, nationwide study (Spain). The recruitment period ended in October 2017. Baseline evaluation included more than 15 validated scales and complementary studies in a subgroup of participants.

Results: In total, 1174 subjects from 35 centres were considered valid for baseline analysis: 694 patients (62.6 ± 8.9 years old, 60.3% males), 273 caregivers (58.5 ± 11.9 years old, 31.8% males) and 207 controls (61 ± 8.3 years old, 49.5% males). The mean disease duration was 5.5 ± 4.4 years. Hoehn and Yahr stage was 1 or 2 in 90.7% of the patients whilst 33.9% and 18.1% of them presented motor fluctuations and dyskinesias, respectively. The mean Non-Motor Symptoms Scale total score was 45.4 ± 38.1, and 30.4% of the patients presented cognitive impairment, 16.1% major depression, 12.7% impulse control disorder, 7.2% compulsive behaviour, 57.2% pain and 13.2% falls. Compared to the control group, PD patients presented a significantly higher burden of non-motor symptoms and a worse quality of life. More than 300 subjects conducted complementary studies (serum biomarkers, genetic and neuroimaging).

Conclusions: Parkinson's disease is a complex disorder and different non-motor symptoms are frequently present and are more prevalent than in controls. In real clinical practice it is important to ask for them.

Keywords: Parkinson's disease; gait; mood; motor fluctuations; non-motor symptoms; quality of life.

PubMed Disclaimer

References

    1. Kalia LV, Lang AE. Parkinson's disease. Lancet 2015; 386: 896-912.
    1. Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson's disease. Nat Rev Neurosci 2017; 18: 435-450.
    1. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR; NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011; 26: 399-406.
    1. Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural instability/gait difficulty groups with the Movement Disorder Society Unified Parkinson's Disease Rating Scale: comparison with the Unified Parkinson's Disease Rating Scale. Mov Disord 2013; 28: 668-670.
    1. Sauerbier A, Jenner P, Todorova A, Chaudhuri KR. Non motor subtypes and Parkinson's disease. Parkinsonism Relat Disord 2016; 22(Suppl. 1): S41-S46.

Publication types

MeSH terms

LinkOut - more resources